Ferring Pharmaceuticals begins treatment of first US patient with ADSTILADRIN
Ferring Pharmaceuticals has announced that the first patient in the United States suffering from high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) has been administered with the intravesical gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg). The gene therapy was approved by the U.S. Food and Drug Administration (FDA) in December 2022 for the treatment of adult […]